FBT vs XBI

Key Takeaways

• FBT tracks the NYSE Arca Biotechnology Index with approximately 30-32 equal-weighted holdings, offering concentrated exposure to leading biotechnology companies, while XBI follows the S&P Biotechnology Select Industry Index with over 150 modified equal-weighted holdings for broader diversification across the sector.
• Both ETFs are passively managed and focus exclusively on U.S. biotechnology stocks within the healthcare sector, but FBT's equal-dollar weighting emphasizes balance among fewer names, whereas XBI's modified equal-weight approach incorporates a wider range of market capitalizations, including smaller companies.
• FBT carries a higher expense ratio of 0.55% compared to XBI's 0.35%, reflecting differences in index methodology and portfolio concentration.
• FBT provides more targeted exposure suitable for investors seeking concentrated bets on established biotechnology leaders, while XBI offers greater diversification and potential for capturing emerging opportunities across the broader biotechnology landscape.
• Both funds exhibit high volatility typical of the biotechnology sector, influenced by clinical trial outcomes, regulatory approvals, and macroeconomic factors such as interest rate expectations.
• Structural differences in holdings count and weighting methodology lead to varying risk profiles, with XBI generally demonstrating lower single-stock concentration risk.

Introduction

Investors seeking biotechnology exposure often compare the FBT and XBI as specialized exchange-traded funds (ETFs) within the healthcare sector. These ETFs do not compete directly as broad market vehicles but provide alternative strategies for accessing the biotechnology sub-industry. FBT delivers concentrated, equal-weighted exposure to a select group of leading companies, while XBI emphasizes broader, modified equal-weighted participation across many more holdings. This comparison highlights their structural distinctions, thematic positioning in the evolving biotechnology landscape, and suitability for different investor objectives amid ongoing sector innovation and regulatory dynamics.

First Trust NYSE Arca Biotechnology Index Fund (FBT) Overview

The First Trust NYSE Arca Biotechnology Index Fund (FBT) is a passively managed ETF that seeks to replicate the performance of the NYSE Arca Biotechnology Index. This equal-dollar weighted index measures the performance of approximately 30 leading biotechnology companies classified within the biotechnology sub-industry. The fund typically holds 30-32 securities, with top holdings including companies such as Corcept Therapeutics, Regeneron Pharmaceuticals, and Amgen, each generally representing around 3-5% of assets. Sector allocation is overwhelmingly concentrated in healthcare, specifically biotechnology. FBT features an expense ratio of 0.55% and employs quarterly rebalancing to maintain equal weighting. Its concentrated structure and focus on established biotechnology names distinguish it as a targeted vehicle for investors prioritizing balance among leading players in drug development and biological processes.

State Street SPDR S&P Biotech ETF (XBI) Overview

The State Street SPDR S&P Biotech ETF (XBI) is a passively managed ETF designed to track the S&P Biotechnology Select Industry Index. This modified equal-weighted index derives from the biotechnology segment of the S&P Total Market Index and includes approximately 150-157 holdings. Top positions, such as Apogee Therapeutics, Moderna, and Twist Bioscience, typically account for 1-1.5% each, resulting in significantly lower concentration. The fund maintains nearly 100% allocation to the biotechnology sub-sector within healthcare. XBI carries a lower expense ratio of 0.35% and rebalances quarterly. Its broader diversification across market capitalizations, including more mid- and small-cap names, positions it as a comprehensive tool for capturing sector-wide biotechnology trends and innovation.

Industry and Thematic Backdrop

The biotechnology sector operates within the broader healthcare industry, driven by advancements in drug development, gene editing, and personalized medicine. Key catalysts include clinical trial results, U.S. Food and Drug Administration approvals, and capital allocation toward innovative therapies. Macroeconomic factors such as interest rate environments influence funding for research-intensive companies, while regulatory developments around drug pricing and intellectual property affect profitability. Sector risks encompass high failure rates in clinical stages, patent expirations, and competitive pressures. Both ETFs benefit from ongoing innovation but remain sensitive to shifts in investor sentiment toward growth-oriented healthcare sub-sectors during periods of economic uncertainty or policy changes.

Performance and Positioning Comparison

In recent market cycles, biotechnology ETFs have shown sensitivity to sector rotation and earnings developments among top holdings. FBT's concentrated equal-weighted approach can amplify returns during periods when its select holdings outperform, but it may also experience sharper drawdowns due to higher individual stock influence. XBI's broader modified equal-weighting tends to moderate volatility by spreading exposure across more names, potentially offering smoother participation in sector momentum driven by smaller innovators. Relative positioning depends on market conditions favoring established leaders versus emerging players. Both funds exhibit elevated volatility compared to broader equity markets, with performance influenced by interest rate expectations, merger and acquisition activity, and overall risk appetite in healthcare investing.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors comparing biotechnology-focused ETFs like FBT and XBI may find the tool useful for refining sector-specific searches.

Tickeron AI Verdict

Based on structural characteristics, Tickeron’s AI would likely favor the State Street SPDR S&P Biotech ETF (XBI) in the current environment due to its lower expense ratio, greater diversification across more holdings, and modified equal-weight methodology that reduces concentration risk while maintaining broad biotechnology exposure. These factors support more consistent trend participation and lower single-name volatility compared to the more concentrated profile of FBT, though both remain viable depending on investor preference for targeted versus comprehensive sector access.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations